Premium
Opioid hearing takes up buprenorphine deregulation and more
Author(s) -
Knopf Alison
Publication year - 2020
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32648
Subject(s) - limelight , buprenorphine , deregulation , opioid , political science , business , advertising , medicine , engineering , economics , receptor , electrical engineering , macroeconomics
The opioid hearing by the House Energy and Commerce Committee March 3 gave everyone a chance to ask questions and answer them, but lawmakers got the lion's share of the limelight as they promoted their respective bills. And the grandstanding wasn't limited to bills on the table: Politicians have never been shy about expressing their opinions on the best way to approach addiction. Still, it was a productive hearing, thanks in large part to the skillful management by Rep. Anna G. Eshoo (D‐California), chair of the Health Subcommittee of the House Energy and Commerce Committee.